Protalix BioTherapeutics Inc (AMEX: PLX) Stock Could Be An Option To Consider

Protalix BioTherapeutics Inc (AMEX:PLX) shares, rose in value, with the stock price down by -0.83% to the previous day’s close as strong demand from buyers drove the stock to $1.78.

Actively observing the price movement in the recent trading, the stock is buoying the session at $1.80, falling within a range of $1.765 and $1.8179. The value of beta (5-year monthly) is 0.672. Referring to stock’s 52-week performance, its high was $1.90, and the low was $0.82. On the whole, PLX has fluctuated by 43.95% over the past month.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

With the market capitalization of Protalix BioTherapeutics Inc currently standing at about $131.44 million, investors are eagerly awaiting this quarter’s results, scheduled for in January.

Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PLX’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.

The stock’s technical analysis shows that the price of PLX currently trading nearly 5.73% and 31.61% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 68.82, while the 7-day volatility ratio is showing 3.22% which for the 30-day chart, stands at 6.06%. Furthermore, Protalix BioTherapeutics Inc (PLX)’s beta value is 0.73, and its average true range (ATR) is 0.07.

A comparison of Protalix BioTherapeutics Inc (PLX) with its peers suggests the former has fared considerably weaker in the market. PLX showed an intraday change of -0.83% in today’s session so far, and over the past year, it grew by 5.00%%.

Data on historical trading for Protalix BioTherapeutics Inc (AMEX:PLX) indicates that the trading volumes over the past 10 days have averaged 0.41 and over the past 3 months, they’ve averaged 291.80K. According to company’s latest data on outstanding shares, there are 73.63 million shares outstanding.

Nearly 7.56% of Protalix BioTherapeutics Inc’s shares belong to company insiders and institutional investors own 5.21% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.1 million shares as on 2024-10-31, resulting in a short ratio of 22.71. According to the data, the short interest in Protalix BioTherapeutics Inc (PLX) stood at 441.00 of shares outstanding as of 2024-10-31; the number of short shares registered in 2024-09-30 reached 3.13 million. The stock has risen by 0.28% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PLX stock heading into the next quarter.

Most Popular